Medley

Medley EBIT per Employee

The EBIT per Employee of Medley (4480.T) as of Nov 12, 2026 is 6.07 M JPY. In the previous year, EBIT per Employee was 6.14 M JPY — a change of -1.16% (lower).

EBIT per Employee

6.07 MJPY

YoY

-1.16%

Last updated:

EBIT per Employee of Medley is 2025 6.07 M JPY. EBIT per Employee of Medley was 2024 6.14 M JPY. It decreases by -1.16% lower compared to the previous year.

The Medley EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-268,540.90 JPY
Jan 1, 2019
404,113.46 JPY
Jan 1, 2020
1.09 M JPY
Jan 1, 2021
2.06 M JPY
Jan 1, 2022
3.52 M JPY
Jan 1, 2023
7.12 M JPY
Jan 1, 2024
6.14 M JPY
Jan 1, 2025
6.07 M JPY
The Medley EBIT per Employee history
YEAREBIT per EmployeeYoY
6.07 MJPY-1.16%
6.14 MJPY-13.78%
7.12 MJPY+102.40%
3.52 MJPY+70.98%
2.06 MJPY+88.73%
1.09 MJPY+169.92%
404,113.46JPY-250.48%
-268,540.90JPY-439.69%
79,055.41JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medley Stock analysis

What does Medley do? Medley Inc is a global company specializing in the production and sale of pharmaceutical products. The company was founded in 1985 as a small business and has since become a leading player in the pharmaceutical industry, operating in over 150 countries. Medley Inc produces a variety of products in different areas such as cardiology, gastroenterology, oncology, orthopedics, neurology, and dermatology. The company's business model is based on the development and sale of generic products, which are imitation products of patented drugs. Medley Inc focuses on producing high-quality and effective medicines at competitive prices. The company has production sites in various countries to meet the demand for drugs in each region. In addition to being a manufacturer of medicines, Medley Inc also offers services such as drug distribution, clinical studies, research and development, consulting for pharmaceutical manufacturers, and customer training. The company places great importance on the quality and safety of its products and services and has implemented a comprehensive quality management system to meet its high standards. The product range of Medley Inc includes a variety of drugs used in different indications, including well-known drugs such as Tamoxifen for cancer, Fluoxetine for depression, Oxycodone for pain relief, and Levofloxacin as an antibiotic. Medley Inc strives to make affordable medications accessible to all people and works to improve healthcare worldwide. The company has formed long-term partnerships with organizations and governments in emerging countries to enhance access to affordable medicines. Overall, Medley Inc is a significant player in the pharmaceutical industry, focusing on the production of generics and improving healthcare globally. Through its efforts in quality, innovation, and partnerships, the company aims to have a positive impact on society. Medley is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medley stock

EBIT per Employee of Medley is 6.07 M JPY in 2025.

EBIT per Employee of Medley changed from 6.14 M JPY to 6.07 M JPY, representing a -1.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Medley since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Medley historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Medley

All Key Metrics — Medley